2014 Update of the Canadian Rheumatology Association/Spondyloarthritis Research Consortium of Canada Treatment Recommendations for the Management of Spondyloarthritis. Part II: Specific Management Recommendations

• Published in: Journal of rheumatology 2015-04, Vol.42 (4), p.665-681
• Main Authors: Rohekar, Sherry, Chan, Jon, Tse, Shirley M L, Haroon, Nigil, Chandran, Vinod, Bessette, Louis, Mosher, Dianne, Flanagan, Cathy, Keen, Kevin J, Adams, Karen, Mallinson, Michael, Thorne, Carter, Rahman, Proton, Gladman, Dafna D, Inman, Robert D
• Format: Article
• Language: English
• Subjects: Anti-Inflammatory Agents, Non-Steroidal - therapeutic use; Antirheumatic Agents - therapeutic use; Canada; Disease Management; Evidence-Based Medicine; Humans; Rheumatology - standards; Spondylarthritis - drug therapy
• ISSN: 0315-162X; 1499-2752
• DOI: 10.3899/jrheum.141001

The Canadian Rheumatology Association (CRA) and the Spondyloarthritis Research Consortium of Canada (SPARCC) have collaborated to update the recommendations for the management of spondyloarthritis (SpA). A working group was assembled and consisted of the SPARCC executive committee, rheumatologist leaders from SPARCC collaborating sites, Canadian rheumatologists from across the country with an interest in SpA (both academic and community), a rheumatology trainee with an interest in SpA, an epidemiologist/health services researcher, a member of the CRA executive, a member of the CRA therapeutics committee, and a patient representative from the Canadian Spondylitis Association. An extensive review was conducted of literature published from 2007 to 2014 involving the management of SpA. The working group created draft recommendations using multiple rounds of Web-based surveys and an in-person conference. Recommendations for the management of SpA were created. Part II: Specific Management Recommendations addresses management with nonpharmacologic methods, nonsteroidal anti-inflammatories and analgesics, disease-modifying antirheumatic drugs, antibiotics, tumor necrosis factor inhibitors, other biologic agents, and surgery. Also included are 10 modifications for application to juvenile SpA. These recommendations were developed based on current literature and applied to a Canadian healthcare context. It is hoped that implementation of these recommendations will promote best practices in the treatment of SpA.